Radionuclides in ionic form can become chemically bound in the airways of the lungs following dissolution of inhaled particulates in lung fluid. The presence of long-term binding can greatly increase lung doses from inhaled plutonium, particularly if it occurs in the bronchial and bronchiolar regions. However, the only published evidence that plutonium binding occurs in humans comes from an analysis of the autopsy and bioassay data of United States Transuranium and Uranium Registries Case 0269, a plutonium worker who experienced a very high (58 kBq) acute inhalation of plutonium nitrate. This analysis suggested a bound fraction of around 8 %, inferred from an unexpectedly low ratio of estimated total thoracic lymph node activity:total lung activity, at the time of death. However, there are some limitations with this study, the most significant being that measurements of the regional distribution of plutonium activity in the lungs, which provide more direct evidence of binding, were not available when the analysis was performed. The present work describes the analysis of new data, which includes measurements of plutonium activity in the alveolar-interstitial (AI) region, bronchial (BB) and bronchiolar (bb) regions, and extra-thoracic (ET) regions, at the time of death. A Bayesian approach is used that accounts for uncertainties in model parameter values, including particle transport clearance, which were not considered in the original analysis. The results indicate that a long-term bound fraction between 0.4 and 0.7 % is required to explain this data, largely because plutonium activity is present in the extra-thoracic (ET 2 ), bronchial and bronchiolar airways at the time of death.
INTRODUCTION
In the International Commission on Radiological Protection (ICRP) Publication 66 human respiratory tract model (HRTM) (1) and in the revised HRTM (2) , the absorption to blood of material deposited in extra-thoracic region ET 2 and the thoracic airways is assumed to occur by dissolution of the inhaled material, followed by uptake to blood. The latter is assumed to be instantaneous unless the dissolved ions of the radionuclide become chemically bound within lung epithelia. The proportion of material that becomes bound after material has dissolved is determined by the bound fraction, f b . Because it occurs after dissolution, binding is dependent on the ionic form of the radionuclide and so is independent of the previous chemical form of the inhaled material. Hence, the value of f b is assumed to be the same for plutonium dioxide (PuO 2 ) and nitrate (Pu(NO 3 ) 4 ). Uptake of material to blood from the bound state is assumed to occur at a rate s b .
The presence of long-term binding can greatly increase lung doses from inhaled plutonium, particularly if it occurs in the bronchial and bronchiolar regions of the lung (3, 4) . However, evidence that it actually occurs for plutonium is unclear. To ensure the reliability of ongoing radiation protection of plutonium workers and the accuracy of retrospective dose reconstruction for epidemiology, it is important to With respect to Point (a), the only published evidence for binding, according to the ICRP definition, derives from an analysis of United States Transuranium and Uranium Registries (USTUR) Case 0269 by James et al. (5) This worker suffered a large acute inhalation of acidic plutonium nitrate 'mist' whilst working at a nuclear defence facility. In an attempt to ameliorate the plutonium burden, Ca-diethylenetriaminepentaacetic acid (DTPA) and Ca-ethylenediaminetetraacetic acid (EDTA) were administered intravenously immediately and again intermittently over the next 2 y. Extensive measurements of plutonium ( 239,240 Pu) activity in urine and faeces were made following exposure until the individual's death. An initial estimate of intake of 58 kBq was determined by James et al. (5) from the lung, thoracic lymph node, urine and faecal measurements; the latter excluded measurements that were made soon after periods of Ca-EDTA/DTPA treatment. In addition to fitting dissolution parameter values, the authors also fitted values of 0.08 for f b and 0.0002 d 21 for s b . Inclusion of a bound fraction was justified by the authors on the basis of the following:
(a) Plutonium activity was still present in the lungs 38 y after exposure; this could only occur if the solubility of the inhaled material was reduced to an extent that is inconsistent with the 'moderately soluble' ICRP Publication 71 'Type M' behaviour that is expected for fresh plutonium nitrate (6) ; (b) If the inhaled material was insoluble, then the ratio of thoracic lymph node to total lung activity was too low for the model to account for it; in other words, plutonium activity had become 'stuck' in the alveolar region of the lungs when the expectation is that it should have been translocated from the alveolar region to the thoracic lymph nodes by macrophage-mediated particle transport. The alveolar retention might therefore be explained by the process of binding as it is defined in the HRTM because bound material is not subject to particle transport clearance.
However, there are several potential limitations with the analysis of James et al.
:
(1) Because other data were unavailable, the analysis considered only the total lung burden and lymph node burden. However, the assumption of a longterm bound fraction can significantly affect the predicted distribution of plutonium activity in the lungs at the time of death and thus provide clues to its existence. For soluble forms, a permanent bound fraction means that a significant amount would be expected in the extra-thoracic (ET 2 ), bronchial (BB) and bronchiolar (bb) regions many years after the intake occurred. In the absence of binding, the same material is cleared from these regions by rapid absorption to blood and particle transport clearance to the alimentary tract. (2) The fitted value of the slow dissolution parameter, s s , (0.0002 d
21
) is inconsistent with the values estimated for plutonium nitrates ( 0.002 d
) from in vivo studies (3, 7) . (3) The authors did not consider uncertainty in the rate of particle transport clearance from the alveolar region, which will affect estimated values of absorption parameters. (4) The HRTM representation of particle transport clearance from the alveolar region has been updated to account for measurements of longterm lung retention of inhaled aerosols that have become available since publication of the HRTM in 1994 (8) . (5 The present analysis addresses these limitations by
(1) Considering new measurements of plutonium activity in the regions of the lung of USTUR Case 0269 derived by Tolmachev (9) ; these include measurements of activity in the following regions: extra-thoracic (ET 2 ) region, bronchial (BB) and bronchiolar (bb) regions, alveolar-interstitial (AI) region and thoracic lymph node (LNTH).
(2) Applying a Bayesian approach to identify ranges of parameter values (as Bayesian posterior distributions) that explain the data, and also accounts for uncertainties on key particle clearance parameters. (3) Using the revised HRTM (2) . (4) In the Bayesian framework, the state of knowledge of a model parameter value is defined as a probability distribution. This knowledge is updated by the application of Bayes' theorem and relevant measurement data:
PðX jMÞ / PðMjX ÞPðX Þ ð 1Þ
where P(MjX) is the probability of observing the new data M, given parameter values X. The probability density function, P(X), describes the initial state of knowledge regarding X; for this reason, it is referred to as the prior distribution. The updated information regarding the parameter is defined by the probability density function, P(XjM): it is the distribution of X conditioned on the data M and is referred to as the posterior distribution. It represents the sum total of knowledge regarding the model parameters represented by the data and the priors. In the present context, M is a vector of the measurements of plutonium in the lungs and systemic tissues, and X is a vector of HRTM parameter values and intake. Such a Bayesian approach has been used in internal radiation protection to identify intakes in routine monitoring (10) and estimate uncertainties on doses from bioassay data (3, 11, 12) .
This paper describes the application of the Bayesian approach in a framework that accounts for existing information regarding the exposure, the HRTM and prior uncertainties on HRTM parameter values, to the data in order to determine whether a non-zero bound fraction, f b , is required to explain it; and, if so, derive plausible ranges for f b and possibly s b . In order to achieve this, the Bayesian analysis comprised two sets of calculations:
Calculation (1) . An initial analysis that used the data considered in the study of James et al.
, namely predicted plutonium ( 239,240 Pu) activity in both lungs (derived from a measurement of activity in the whole right lung), partially collected thoracic lymph nodes, urine and faecal data. This was undertaken to determine whether the data considered by James et al. (5) could be explained by the current state of knowledge regarding the HRTM without the need to invoke use of the bound fraction. Calculation (2) . An analysis that considered new measurements of plutonium activity in the different regions of the left lung, the lymph node activity and the systemic plutonium burden (the combined skeleton and liver activity). This analysis provides a definitive assessment of binding, and furthermore, aims to avoid potential bias introduced by the effect of the DTPA treatment. This is achieved by performing two separate Bayesian analyses, where:
(1) The lung data were considered with the measurements of total skeleton and liver 239,240 Pu activity. (2) The lung data were considered with measurements of skeleton and liver 239,240 Pu (systemic) activity that would have been expected had the Ca-EDTA/DTPA treatment not been given.
Lung measurements for Calculation (2)
The lung 239, 240 Pu measurements considered in Calculation (2) were scaled to give the predicted activity in these regions for both lungs; these are summarised in Table 1 . Activity in the bronchial and bronchiolar regions was combined to give total tracheaobronchial/bronchiolar (TB) activity. The derivation of the 239, 240 Pu activities in the different lung regions is described by Tolmachev. (9) With the exception of the thoracic lymph nodes, the measurement uncertainties were assumed to be normally distributed and largely reflect counting statistics. Other potential sources of uncertainty were assumed to be small because the measurements were obtained from all of the left lung tissues and half the trachea. When adjusted for differences in mass, these predict accurately the activity in the left lung that was used to obtain the total lung activity used in the analysis of James et al. (5) It was also considered that additional sources of potential error such as misidentification of tissue during sample dissection are difficult to quantify and in any event, likely to be minimal. The measurement uncertainty of the LNTH was assumed to be lognormally distributed with a GSD of 1.4. This was assumed because the activity predicted in the LNTH was obtained by scaling a partial measurement of 239, 240 Pu in LNTH tissue by the ICRP reference mass of 15 g (13) . It was assumed that the uncertainty on LNTH activity for this individual is mostly dominated by uncertainty in the actual mass of the tissue; the assumption of lognormality and the GSD of 1.4 are based on the variability in the mass of this tissue published by ICRP (13) .
Systemic measurements for Calculation (2)
Because it appears likely that the systemic retention of plutonium was significantly affected by the protracted administration of Ca-EDTA/DTPA during the first 1 y following exposure, the urine and faecal data were not included in Calculation (2) . However, the systemic burden at death was included, and the potential confounding effect of Ca-EDTA/DTPA administration was accounted for by performing the analysis alternately using two sets of systemic measurements. The first set ['observed (with DTPA)' in Table 1 ] is the combination of the estimated skeleton and liver activity derived from measurements of 239, 240 Pu in these tissues obtained at autopsy; the second set ['predicted (without DTPA)' in Table 1 ] is the combination of the skeleton and liver activity that would have been observed in the absence of Ca-EDTA/DTPA treatment, assuming the efficiency of this treatment in reducing the systemic plutonium burden inferred by James et al. (5) . Pu content in a tissue at the time of death based on measured concentration in autopsy samples. b Uncertainties assumed to be normally distributed for all tissues except LNTH, which is assumed to be lognormally distributed with a geometric standard deviation (GSD) of 1.4.
METHODS

Biokinetic models
All analyses were performed assuming the revised ICRP Publication 67 model (14) for plutonium published by Leggett et al. (15) The revised HRTM (2) including reference particle transport clearance rates and breathing parameters, assumed for the analysis of Mayak workers under MWDS-2013 (16) was used in this analysis.
Prior distributions used in Calculation (1)
The prior distributions used to analyse the original lung and bioassay data are summarised in Table 2 .
Absorption parameters
The purpose of this calculation was to essentially reproduce the analysis of James et al. (5) in a probabilistic framework that accounted for the current state of knowledge regarding HRTM particle transport clearance. For this reason, uninformative uniform distributions, which do not favour one parameter value over another, were assumed for the absorption parameters.
Particle transport parameters
The prior distributions assumed for the clearance rates from the alveolar region, and the factor, K PT , used to scale the mucociliary clearance rates, are those assumed for the analysis of Mayak workers under MDWS-2013 and summarised by Birchall et al. (16) .
Intake
Previous estimates in James et al. (5) suggest an intake of around 58 kBq. However, these were based on the same bioassay and autopsy data used in the present analysis. Furthermore, it is possible that this estimate is biased given the effect of the DTPA treatment on the bioassay and systemic data. Because these data are highly informative with respect to the prior information for this parameter (its posterior distribution is determined almost exclusively by the likelihood), a broad uniform prior distribution on total intake-sufficient to cover all intake values supported by the likelihood-was assumed with a lower bound of 0 Bq and an upper bound of 1 10 6 Bq.
Prior distributions used in Calculation (2)
The prior distributions used to analyse the new autopsy data are summarised in Table 3 .
Absorption parameters
In order to permit only the data (likelihood) to inform on the posterior values, uniform prior distributions were assumed for the slow dissolution rate, s s , and the bound fraction, f b . This was justified on the basis of the following:
(a) It was assumed that there are currently no estimates of f b from other studies that could form the basis of an informative prior for this parameter. In addition to the study of James et al. (5) , the only other application of the bound state has been to fit Mayak autopsy data by Khokryakov et al. (17) ; however, in this case, its use appears to simply provide a modelling mechanism to retain plutonium in the lungs at late times using the ICRP Publication 66 HRTM (1) (which under-predicts retention of insoluble particulates at late times), and so does not provide reliable a priori estimates of f b . Because of the large timescale between the time of exposure and the time of death, the rapid fraction, f r , was fixed at a value of 0.17, the median value of the prior distribution derived for the analysis of European plutonium workers (3) and used in MWDS-2013 (16) . However, the range of plausible values of the rapid rate, s r , overlaps the rate of particle transport clearance from the bronchial/bronchiolar region and thus may affect the regional distribution of plutonium 
Prior distributions for intake and HRTM aerosol deposition and clearance parameters used in the analysis of the original data for USTUR Case 0269. a Prior for AMAD assumed in MWDS-2013, taken from Puncher et al.
. b
Rates from the alveolar (ALV) region to bronchiolar region (bb), and interstitial region (INT) are taken from Gregoratto et al. (8) . c Rate from interstitium (INT) to thoracic lymph node (LNTH) taken Puncher et al. (3) . d Particle transport rates in the BB, bb and ET compartments are multiplied by factor K PT .
in the lungs if long-term binding occurs. For this reason, the informative prior derived for s r for plutonium nitrate materials by Puncher et al. (3) was assumed, which has a median value of 1 d 21 . Initial Monte Carlo investigations with the autopsy data showed that it was not possible to simultaneously identify values of f b and s b , a consequence of the high degree of negative correlation introduced between these parameters by this data. Because the purpose of the investigation was primarily to determine whether a long-term/permanent bound fraction was required to explain the data, the rate from the bound compartment to blood, s b , was fixed at zero.
Particle transport parameters
The prior distributions assumed for the clearance rates from the alveolar region and the factor K PT are the same as those used in Calculation (1). In addition, prior uncertainty was also included for the fraction of activity deposited in the TB and ET 2 regions that is sequestered by macrophages in the lamina propria of the airways. For this, a broad uninformative lognormal prior distribution was assumed with a median value equal to the revised reference value of 0.002, taken from the study by Smith et al. (18) , and a GSD of 3. The prior for the reference rates of removal from the sequestered compartment to lymph nodes in the TB and ET 2 regions was based on a review of uncertainties in particle transport clearance published by ICRP (1) , but assuming the revised values published by Smith et al. (18) ; these rates were scaled by a common factor K PT(seq) , sampled from a lognormal distribution with median value of unity and a GSD of 1.73.
Intake
For Calculations (1) and (2), a broad uniform prior distribution was assumed for intake with a lower bound of 0 Bq and an upper bound of 1`Â 10 6 Bq.
Markov Chain Monte Carlo calculations
Bayesian inference was performed using the Markov Chain Monte Carlo (MCMC) method described by Puncher and Birchall (19) and Puncher et al. (20) The MCMC routines use the software IMBA Professional Plus (21) to calculate bioassay predictions. The MCMC method is an implementation of the singlecomponent Metropolis algorithm (22) . In brief,
(1) For each analysis, two chains were initiated using different values of parameters with positive density in the posterior distribution. (2) For subsequent iterations, proposed parameter values were sampled from normal distributions in the usual way (19) . The values from two separate chains were obtained using pseudo-random number generators seeded with different values. For each set of sampled parameter values, a maximum likelihood estimate of intake was obtained. This was recorded together with the x 2 value and corresponding x 2 alpha probability value. (3) Chains were run out to between 2`Â 10 4 and 10`Â 10 4 iterations; the first 1000-2000 iterations were discarded to allow for burn-in of the chains after which the initial chosen values and their immediate influence on the location of the sampled parameter values are 'forgotten' and so do not influence posterior estimates of parameter values.
The following MCMC analyses were performed:
Calculation MCMC1: Two separate runs were performed: one that included the prior on f b and s b , and the other where f b was fixed at a value of zero. Calculation MCMC2: Two analyses were performed: one using the observed measurement of systemic activity, and the other using the systemic activity 
. b The amount incorporated into compartments ET seq , BB seq and bb seq in the HRTM (2) . c Rates from the alveolar (ALV) region to bronchiolar region (bb), and interstitial region (INT) are taken from Gregoratto et al. (8) . d Rate from interstitium (INT) to thoracic lymph node (LNTH) taken Puncher et al. (3) . e All rates in the BB, bb and ET compartments, other than those in the sequestered compartments are multiplied by factor K PT . f Rates from compartments ET seq to extra-thoracic lymph nodes (LNET) and BB seq /bb seq to thoracic lymph nodes (LNTH) scaled by common factor K PT(seq) . g Distribution left-truncated at 0.1, taken from Puncher et al. (3) .
predicted to have been present if Ca-EDTA/DTPA had not been administered (see Table 1 , 'without DTPA treatment'). For each analysis, two separate MCMC runs were performed: one that included the prior on f b , and the other where f b was fixed at a value of zero. Note that the prior distribution on the sequestered fraction was only included in the latter analysis.
RESULTS
Calculation MCMC1: Bayesian analysis of original lung, lymph node, urine and faecal data
Estimates of the posterior means of HRTM parameters, intake and x 2 values obtained from the MCMC analysis of the original autopsy, urine and faecal data considered by James et al. (5) are summarised in Table 4 . The corresponding point estimates obtained by them are also provided. For convenience, the row labelled 'Defaults' in Table 4 gives the values of absorption parameters for plutonium nitrate materials derived from a review by Puncher et al. (3) of published in vivo studies, and the maximum x 2 value that is consistent with conventional acceptable goodness-of-fit criteria for these data (a x 2 alpha probability value of 0.05). The main points of interest are as follows: † When the bound-state parameters, f b and s b , were included in the present analysis (Table 4 , 'this analysis with binding'), posterior estimates are generally in good agreement with the values obtained by James et al. (5) through iterative fitting. Any differences are likely due to fundamental differences in the analytical and modelling approaches used in this and the original work. For example, use of the ICRP publication 66 HRTM by James et al. (5) probably accounts for the fact that the value of f b estimated by James et al. (5) is a factor of 4 higher than that determined here. † In the absence of binding ( Table 4 indicate that the model and prior distributions do not explain all of the data: the x 2 values are around a factor of two or more higher than the maximum value that corresponds to an alpha probability value of 0.05. Closer inspection of sets of parameters sampled in the MCMC analysis giving the best fits to the data indicates that this results from poor fitting of the urine and faecal data, rather than discrepancies between the HRTM and the lung and lymph node measurements; as also observed by James et al. (5) , these are adequately described by the model and sampled parameter values. Indeed, because the assumed measurement uncertainties are very small, the sampled parameter values result in lung and lymph node predictions that are almost in exact agreement with the measured values.
Calculation MCMC2: Bayesian analysis of new regional lung data and systemic measurements
The Bayesian analysis of the data derived from the autopsy and tissue analysis described by Tolmachev et al. (23) are presented in Tables 5 and 6 , and these tables summarise the analyses that included or excluded a bound state (a prior on f b or f b fixed at zero), respectively. For brevity, the tables do not include the posterior estimates of AMAD and the rapid rate, s r , as it was found that the data were not n/a n/a 4.4 21 849
Comparison of posterior mean estimates of model parameter values (this analysis, with and without binding), with point estimates determined by James et al. (5) (with binding; i.e. f b is non-zero) using original lung, lymph node, urine and faecal data for USTUR Case 0269 published by James et al. (5) . a x 2 value can be compared with a value of 375, which corresponds to an alpha probability of 0.05 (assuming 332 degrees of freedom).
informative for these parameters and were therefore similar in both analyses. The main points of interest are as follows: † Goodness of fit. Both analyses yield distributions of x 2 alpha values that indicate consistency between model, sampled parameter values and data, although it appears that the inclusion of binding, as opposed to setting f b ¼ 0 and varying the TB/ET 2 sequestered fraction, better explains the data: the median x 2 alpha value for the former is a factor of four higher than the corresponding value for the latter. However, the important point is that good fits to the data can be obtained from sampled parameter values when binding is included or excluded ( f b is set to zero) from the analysis. † Binding included. When binding is included (Table 5) , the rate of slow dissolution assumes values that are comparable with those collated for Analysis performed including a prior on the bound fraction, f b , using the lung with either the measured skeleton þ liver activity ('actual with DTPA') or the activity in skeleton þ liver predicted in the absence of DTPA treatment ('actual without DTPA'). a Values are taken from the following: s s , median of values collated by Puncher et al. (3) from existing animal and human in vivo studies; f b , value determined by James et al. (5) ; K PT , K PT(seq) , values corresponding to ICRP Publication 66 (1) default particle transport clearance values; rates 'ALV to bb', 'ALV to INT' and 'INT to LNTH' are those assumed by ICRP (2) ; intake, value fitted by James et al. (5) . (3) from existing animal and human in vivo studies; f b , value determined by James et al. (5) ; K PT , K PT(seq) , values corresponding to ICRP publication 66 default particle transport clearance values; rates 'ALV to bb', 'ALV to INT' and 'INT to LNTH' are those assumed by ICRP (2) ; intake, value fitted by James et al. (5) . Analysis performed assuming no binding ( f b fixed at zero), using the lung with either the measured skeleton þ liver activity ('actual with DTPA') or the activity in skeleton þ liver predicted in the absence of DTPA treatment ('predicted without DTPA'). plutonium nitrate bearing materials by Puncher et al. (3) but are around an order of magnitude higher than the values determined from the analysis of Mayak worker autopsy data (24) . The systemic burden that is predicted in the absence of DTPA treatment has a predictable effect on the values of HRTM parameters and intake: for example, assuming the higher systemic burden predicted by James et al. (5) in the absence of DTPA treatment produces an increase in the rate of slow dissolution and decreases the value of f b , which is consistent with a reduction in the lung to systemic activity ratio predicted in the absence of the DTPA treatment. With the exception of the rate from the ALV to bb region and the rate from INT to LNTH, posterior estimates of particle transport parameters are consistent with the 95 % range of values supported by their prior distributions. The posterior mean particle transport rate from the ALV to bb region is a factor of 58 higher (Table 5 , 'actual with DTPA') and 35 higher (Table 5 , 'predicted without DTPA') than the prior median value (0.0013, Tables 2 and 3), whereas posterior mean particle transport rate from the INT to LNTH is a factor of 14 higher (Table 5 , 'actual with DTPA') and 23 higher (Table 5 , 'predicted without DTPA') than the prior median value (0.00003, Tables 2 and 3 ). The 'shift' in posterior values of these particle transport clearance parameters is required in addition to a positive value of f b to explain the fact that 31 % of the lung activity is still present in the TB region at the time of death: assuming that the posterior means of the parameters in Table 5 predict 33 % in the TB region 40 y after exposure, whereas performing the same calculation but assuming the default particle transport rates (the prior median values) gives a predicted value of 6 % in the TB region.
Given the significant activity in the TB region, it is perhaps surprising that the values of f b are ,1 %. However, it should be remembered that the value of f b affects binding in all regions of the lung where dissolution occurs, including the alveolar-interstitial (AI) region. It was found that if non-zero values of f b were only permitted in the TB region (effectively 'switching off ' binding in the AI region), then the posterior mean value of f b increases to around 5 %. Thus, it appears that the presence of activity in the AI region constrains the range of values that f b can assume. Interestingly, this modification resulted in posterior estimates of the rate from the ALV to bb region that were in better agreement with the prior (an observed median value of 0.0024 can be compared with the prior median of 0.0013); in contrast, the rate from INT to LNTH is now around a factor of 10 or more lower than the prior median value (2`Â 10 ; such a reduction is also observed in the absence of binding (below): † Binding excluded. When f b is set to zero and the prior on binding is replaced with a prior on the sequestered fraction in the upper airways (Table 6 ), the rate of the slow dissolution values is around an order of magnitude lower than that observed in the analysis where binding was included (Table 5) . These values are similar to those determined from the Mayak worker autopsy data described by Puncher et al. (24) With the exception of K PT , and the rate from the INT to LNTH, the posterior estimates of the particle transport parameters are broadly consistent with the 95 % range of values supported by their prior distributions; however, shifts in the median values of the distributions of these parameters can be explained by the fact that f b is set to zero and activity is present in the ET 2 and TB regions that must be accounted for. For example, the posterior median of the TB and ET 2 sequestered fraction is a factor of 5 higher than its prior value; the posterior median of the rate of removal of material sequestered in the TB and ET 2 regions is reduced by a factor of 10 with respect to the prior value. The reduction in the rate of transfer from the INT to LNTH may occur to compensate for the reduction in the rate of slow dissolution.
The most striking observation is that the rate of mucociliary clearance, as represented by the variable, K PT , is reduced by a factor of 1000, which is clearly inconsistent with the 95 % range of values supported by the prior distribution. The prior assumes that overall particle transport varies within a factor of three of the model reference values.
DISCUSSION
In the HRTM, the bound fraction ( f b ) determines the fraction of free ions that are assumed to become chemically bound within lung epithelia following particle dissolution. This paper describes the application of Bayesian inference to determine if a non-zero value of f b is required to explain the autopsy and bioassay data from USTUR Case 0269; a worker who suffered a significant acute inhalation of plutonium nitrate. Application of the technique to interpret the data considered in a previous analysis of this case by James et al. (5) Calculation (1) produces estimates of absorption parameter values that are consistent with their analysis when the fundamental differences in the two approaches are considered. In common with the analysis of James et al. (5) , the fitted parameter values appear to explain the lung and LNTH data but poorly fit the urine and faecal data. The latter is likely due to the effect of the Ca-EDTA/DTPA treatment on systemic retention of plutonium. Importantly however, the results of Calculation (1) demonstrate that the lung and LNTH data considered by James et al. (5) can also be explained without invoking the bound state. Under these circumstances, assessing whether or not the results support a non-zero value of f b can only be determined by inspection of the posterior distributions of parameter values. If the range of posterior values is considered less plausible under the assumption that binding does not occur ( f b fixed at zero) compared with the alternative assumption that binding does occur ( f b has a value greater than zero), then this provides some evidence that binding occurs. In this analysis, it is the dissolution parameters that have posterior ranges of values that are inconsistent with expected values. However, this occurs irrespective of whether binding is included or excluded from the analysis; in particular, the slow dissolution rate s s is either an order of magnitude too high (Table 4 , James et al. (5) ; and 'this analysis with binding') or two orders of magnitude too low (Table 4 , 'this analysis without binding') compared with the value expected for plutonium nitrate materials (Table 4 , 'defaults'). The original lung and lymph node data considered by James et al.
(5) therefore do not provide any evidence for or against binding (a non-zero value of f b ).
Bound material is not subject to particle transport clearance. In the absence of binding ( f b fixed at 0), the HRTM predicts that no activity deposited in the airways should remain in the ET 2 or TB regions 38 y after the exposure: immediately following deposition, soluble material is rapidly absorbed to blood, whereas insoluble material is quickly transferred to the alimentary tract via particle transport clearance. It is therefore surprising that the new data reveal significant activity in these regions so long after the exposure. The Bayesian approach applied in Calculation 2 provides an objective way to determine whether a non-zero bound fraction is required to explain the presence of this activity by assessing whether it can also be explained by another region of the prior parameter space when the bound fraction, f b , is fixed at zero. The results show that the data can be explained by sampled parameter values in the presence or absence of binding, as indicated by the posterior distributions of x 2 alpha values. As expected, in the absence of binding, the calculation favours values of other HRTM parameters that retain activity in the ET 2 and TB regions at late times: the slow rate of dissolution and the factor K PT , which determines the rate of particle transport clearance from the ET 2 and TB regions, are both reduced; and sequestration in the airway walls is increased. Strikingly, however, the factor K PT must be reduced by an implausible three orders of magnitude in order to do so; in effect, mucociliarymediated particle transport clearance must effectively be 'switched off ' in the ET 2 and TB regions in order to explain the presence of plutonium activity in these regions when f b is fixed at zero.
It is noteworthy that in the presence of binding, the data appear to favour more extreme regions of the prior parameter space for the rate of clearance from the ALV to bb region and the rate from the INT to LNTH. This suggests that, even in the presence of binding, the model as represented by the HRTM structure and prior distributions of parameter values has some difficulty explaining all of the data simultaneously; particularly since 31 % of the lung activity is still in the TB region at the time of death, which contrasts with a predicted value of 6 % assuming an f b value of 1 % using the HRTM reference values for particle transport clearance (authors calculations). That this difficulty is at least partially related to the assumed kinetics of binding is suggested by the fact that disabling binding in the alveolar region results in a 5-fold increase in the posterior value of f b and a posterior value of the rate of transfer from the ALV to bb region that is more consistent with its prior value. On this note, it should be emphasised that the measurements only provide an indication of the presence and amount of plutonium in the ET 2 and TB regions, and therefore do not provide definitive evidence that the activity is retained in these regions by the process of chemical binding as it is assumed to occur in the ICRP Publication 66 (1) model: dissolution of inhaled particulates followed by uptake and binding within epithelia. In accordance with this model, it is expected that this material would be distributed uniformly throughout the interior of lung epithelia, as it is assumed in the HRTM dosimetry model (1) . Consequently, the presence of particulate material in these regions at death may indicate that activity is retained by some alternative, or additional, mechanism to chemical binding. Evidence for this is suggested by autoradiography of lung tissue obtained from this donor and Beagle dogs who were administered plutonium nitrate aerosols by inhalation (24) . These indicated the presence of very localised, possibly particulate, material in the interstitial tissue of conducting bronchioles (USTUR Case 0269 and Beagle dogs) and the bronchovascular interstitial tissue of bronchi (Beagle dogs only). This suggests that an alternative, or additional, retention mechanism might be 'physical binding', where particulate material has become immobilised and rendered insoluble as a result of encapsulation in some kind of biological matrix. It might be argued that for dosimetry purposes, f b can be used to represent this mechanism in addition to 'chemical' binding as it is described by the HRTM. However, this assumption has two potential implications for dosimetry in the TB region because: (A) The proximity of 239, 240 Pu to target cells may well be different for physically bound material compared with chemically bound, resulting in different (likely lower) doses to cells in the TB region from the former; and (B) The extent to which material becomes chemically bound is not just dependent on the magnitude of f b but also on the rate of dissolution. Therefore, if f b is used to represent a binding process that depends on some mechanism other than dissolution, then it may well result in doses to the lung being underestimated for insoluble forms of plutonium, including those from plutonium dioxide. That this will likely occur is supported by the fact that an f b value of 1 % results in only 0.001 % of lung activity remaining in the TB region 40 y after exposure to plutonium oxide (author's calculations using IMBA Professional Plus (21) ) compared with 6 % observed for nitrate (above)-thus resulting in TB doses for the former being significantly lower than the latter.
A point of note is the effect that assuming whether binding occurs or not has a significant influence on posterior estimates of the slow dissolution rate, s s . In the presence of binding, the posterior value of 0.0024 -0.0048 d 21 is more consistent with published values for 'soluble' plutonium nitrate (7) and the results of a re-analysis of Harwell volunteers exposed by inhalation (under controlled conditions) to plutonium nitrate (25) . In the absence of binding, the posterior mean value of 0.0002 d 2 1 is closer to the value derived from the analyses of Mayak worker autopsy data (26) . Consequently, whether the observed differences in the posterior estimates of s s provide any evidence for or against long-term binding of plutonium is difficult to judge. This discrepancy in s s and its implications is discussed further by Birchall et al. (16) . The results of Calculation MCMC2 are broadly similar between the analyses that used the observed systemic activity (the plutonium activity remaining in the skeleton and liver at death after protracted Ca-EDTA/DTPA treatment) and those that use the systemic activity that would be predicted in the absence of treatment. Consequently, inference regarding the existence of a bound fraction is unaffected by the Ca-EDTA/DTPA treatment. Nevertheless, the assumed systemic burden does affect the range of values of f b supported by the data when binding is assumed to occur; from the actual data, the posterior value of f b is narrowly distributed around 0.7 %; in the absence of treatment, it is narrowly distributed around 0.4 %. Given that the efficacy of the treatment is also a source of uncertainty, and assuming that this lies somewhere between the full effect predicted by James et al. (5) and no effect, then a value of f b between 0.4 and 0.7 % is inferred from this analysis (Table 5) .
CONCLUSION † Measurements of plutonium in the lungs of USTUR Case 0269 indicate that-surprisinglyplutonium activity is still present in the extrathoracic (ET 2 ) and tracheobronchial and bronchiolar (TB) regions of the lungs, in addition to the alveolar-interstitial (AI) region, 38 y after the intake occurred. A Bayesian analysis is performed to determine whether activity in the ET 2 and TB regions can be explained by chemical binding of plutonium in the airways as it is currently described in the HRTM published by ICRP (2) . † The results indicate that, in the absence of binding, particle transport clearance from the ET 2 and TB regions must be reduced by an implausible three orders of magnitude to account for the presence of activity in these regions at the time of death. This strongly suggests that some mechanism, apart from a reduction in particle transport clearance and particle dissolution, is required to explain the presence of plutonium activity in the TB and ET 2 regions at very late times. The assumption of a non-zero bound fraction, f b , provides a convenient mechanism for doing so within the structure of the HRTM. Under this assumption, the results suggest a value of f b between 0.4 and 0.7 %. † In the HRTM, binding is represented as a process of 'chemical binding'-particle dissolution followed by chemical binding of free ions within lung epithelia. Evidence from other studies suggests that some of the activity represented by f b in this study may in fact result from 'physical binding'-physical immobilisation of insoluble particulates in lung tissues. Physical binding is not represented within the current HRTM.
ADDENDUM
Following completion of the original work described in this paper, the authors have adopted the simulation code, MCSim (Bois and Maszle 1997), which, unlike the code used to perform the original calculations in this paper, is faster and capable of analysing the complete Mayak autopsy dataset for MWDS-2016. For this purpose, MCSim (version 5.6.3) model files have been configured to implement the MWDS-2013 biokinetic models; these assume a fixed lung deposition pattern obtained using the MWDS-2013 deposition parameter values (based on an aerosol AMAD of 4.4 mm-the prior median value in Table 3 ). The code has been used to re-analyse the new autopsy data presented in this paper. Simulations run with MCSim give results that re-enforce the conclusions of the paper. For calculation MCMC 2 (no binding), the goodness of fit is also comparable with that reported here, and similar shifts in the same parameters occur in order to explain the observed lung retention at late times in the absence of binding: particle transport from the TB/ET 2 region is greatly reduced (by a factor of 200 or more in this case) and the rate of slow dissolution is reduced to values more consistent with insoluble forms (,0.0002 d
21
). However, the results of the new simulations also suggest the following: † Incomplete convergence may have occurred for some parameters reported in Table 5 . This is inferred because the new simulations show no difference in the values of parameters obtained in the presence or absence of DTPA treatment, other than those expected for intakes and the bound fraction (as reported above), whereas the results reported here, although broadly similar to those obtained in the new simulations, do suggest small differences in the rate of slow dissolution and particle transport clearance from the alveolar-interstitial region. † The results reported in Table 6 may be samples from an extended burn-in or bi-modal distribution because typically for the first 10 4 iterations, and some complete simulations, the MCSim code gives values of the slow dissolution rate of around 0.00015 -0.00020 d 21 , but then these are reduced to values below 5`Â 10 25 d 21 . However, these are still clearly incompatible with those observed for nitrates. This observation, and the fact that convergence could not be achieved for all parameters in the new simulations when binding was excluded (implying this is an inadequate model), may be taken as further evidence for a bound fraction.
The simulations did not include the prior on AMAD; however, scoping calculations assuming a deposition pattern based on an AMAD of 1 or 14 mm did not affect the estimates of f b or observed changes in the rate of TB/ET 2 clearance in the absence of binding. As above, apart from the bound fraction and intake, there were no evident differences in the values of other parameters obtained in the presence or absence of DTPA treatment.
It is stressed that these newer calculations do not affect the main conclusions derived in this paper, but rather caution against over interpretation of some of the parameter values derived in Tables 5 and 6. 
